Insider Trading Tue 3/12/24

Notable purchases -- Chief R&D Officer adds to KDP; notable sales -- CBO active in RARE

Buyers:

• CRBP 10% owner Cormorant Asset Management bought 550,000 shares at $37.53 - $46.00 worth ~$23.3 mln.
• CSV Director bought 5,000 shares at $26.10 worth ~$131K.
• FGEN CEO bought 50,000 shares at $1.9094 worth ~$95K.
• HWBK Director bought 5,000 shares at $19.90 - $20.645 worth ~$102K.
• KDP Chief R&D Officer bought 4,075 shares at $29.11 worth ~$119K.
• MOFG CEO bought 4,447 shares at $22.4866 worth ~$100K.

Sellers:

• ATR Segment President and one (1) Director sold 5,500 shares combined worth ~$785K.
• LKFN EVP sold 5,247 shares at $66.75 worth ~$350K.
• MDC Director sold 6,200 shares at $62.69 worth ~$389K.
• RARE Chief Business Officer & EVP sold 11,509 shares at $49.92 - $50.06 worth ~$575K.
• USNA Executive Chairman and COO sold 16,251 shares combined at $48.98 - $49.16 worth ~$797K.

This week's biggest % winners & losers : Oct. 16 - 20, 2017 (wk 42)

The following are this week's top 20 percentage gainers and top 20 percentage losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top 20 % gainers

• Healthcare: SPPI (19.32 +44.61%), CRBP (7.75 +13.97%), CYH (6.44 +11.61%), THC (14.66 +11.48%), TXMD (5.11 +11.46%)
• Materials: VHI (3.36 +14.68%)
• Industrials: GWW (207.81 +14.78%), SALT (8.2 +13.1%),
• Consumer Discretionary: SKX (33.99 +39.59%), ASNA (2 +12.36%), EXPR (6.62 +12.2%), BOOT (8.3 +11.71%), SCSS (33.99 +10.97%)
• Information Technology: TEAM (50.01 +26.16%), SYNT (24.22 +24.88%), NPTN (5.46 +15.43%), CREE (33.82 +15.17%), ADBE (175.46 +13.99%)
• Energy: CLD (4.58 +25.14%)
• Utilities: TERP (13.56 +13%)

This week's top 20 % losers

• Healthcare: ARDX (5.55 -23.71%), MNKD (4.13 -21.85%), TRVN (1.76 -19.63%), CELG (121.4 -11.04%)
• Materials: KLDX (3.22 -16.15%), HMY (1.66 -11.7%)
• Industrials: UAL (59.9 -11.35%)
• Consumer Discretionary: TACO (12.65 -16.61%), CTRP (48.43 -12.25%)
• Information Technology: SNCR (11.43 -19.22%), BMI (43.8 -14.79%), BHE (30.5 -14.08%), NCR (33.05 -11.96%), AAOI (41.41 -11.91%), MTSI (36.99 -11.06%)
• Financials: VIRT (14.3 -16.13%)
• Energy: KEG (10.58 -14.75%), FMSA (3.88 -14.73%), SPN (8.85 -12.98%)
• Consumer Staples: SVU (15.03 -25.59%)

Corbus Pharma (CRBP) : mid-stage results for inflammatory disease drug

• The drug, anabasum, is intended for the rare inflammatory condition dermatomyositis, which is associated with an itchy and painful rash and progressive muscle weakness, according to the Mayo Clinic. 

Corbus Pharma announces 'positive' topline results from its Phase 2 study of anabasum in dermatomyositis

• The mean improvement (reduction) in the primary efficacy outcome, the Cutaneous Dermatomyositis Disease Area and Severity Index ("CDASI") activity score, a validated outcome measure of skin disease severity, was 9.3 points for anabasum treatment at the end of the study versus a reduction of 3.7 points for placebo treatment.
• Anabasum also outperformed placebo in multiple secondary efficacy outcomes studied.

***

In the clinical trial, which enrolled 22 adults and lasted 16 weeks, the drug outperformed the placebo in the primary efficacy outcome and in multiple secondary efficacy outcomes, the company said. There were also no signs of safety issues, Corbus said. Currently, "we have little to offer patients with moderate to severe disease activity except immunosuppressive therapies with often limited efficacy and significant side effects," said Dr. Victoria Werth, a principal investigator in the study and a professor of dermatology at the Hospital of the University of Pennsylvania. Corbus Pharma shares have surged 6.9% over the last three months to $7.00 per share.

** charts day before  announcement **

  

CRBP — is it a buy?

• 9 May 2017:  Right after earnings.  Is CRBP a buy?

  

• In the next 5 months:

Corbus Pharma (CRBP) reported earnings on Tue 9 May 2017 (b/o)

• Headquarters: Massachusetts
• Founded: 2009
• corbuspharma.com

NORWOOD, Mass. (AP) _ Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $7.5 million in its first quarter.

The Norwood, Massachusetts-based company said it had a loss of 16 cents per share.

The drug developer posted revenue of $1.3 million in the period.

Corbus Pharmaceuticals shares have fallen 27 percent since the beginning of the year. The stock has more than doubled in the last 12 months.

********

Description

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Key stats and ratios

	Q2 (Jun '17)	2016
Net profit margin	-2083.70%	-1046.27%
Operating margin	-2082.17%	-1045.56%
EBITD margin	-	-1040.97%
Return on average assets	-61.51%	-130.02%
Return on average equity	-72.11%	-223.40%
Employees	25